Programmed death-ligand 1 (PD-L1) expression, initially introduced for guiding immunotherapy in non-small-cell lung cancer (NSCLC), remains the most used companion diagnostic across several malignancies [2]. Here, CD274 is linked to non-small cell lung carcinoma.